KaydedilenlerDerginizi ekleyin

Dergiler / International Journal of Medical Biochemistry / 2022 / Cilt: 5 - Sayı: 2

Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease

Buket AKCAN
Deniz Aksu ARICA
Serap Ozer YAMAN
Sevgi BAHADIR
Asim ÖREM
Burak AKSAN
Birgul KURAL
Fulya Balaban YUCESAN
Sayfa
89–95
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: It was concluded that circulating sTWEAK and its scavenger receptor sCD163 levels were increased in BD, significantly predicted the disease, and might be significant molecules to assess inflammation.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Behçet’s disease (BD) is a chronic multisystemic inflammatory disorder and is associated with many inflammatory processes.
📊
Temel Bulgular & Veri:The present study aimed to examine the serum levels of proinflammatory cytokine soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and its scavenger receptor soluble cluster of differentiation 163 (sCD163) simultaneously in patients with BD by considering their relationships with disease activity.
💡
Sonuç & Katkı:Conclusion: It was concluded that circulating sTWEAK and its scavenger receptor sCD163 levels were increased in BD, significantly predicted the disease, and might be significant molecules to assess inflammation.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: Behçet’s disease (BD) is a chronic multisystemic inflammatory disorder and is associated with many inflammatory processes. The present study aimed to examine the serum levels of proinflammatory cytokine soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and its scavenger receptor soluble cluster of differentiation 163 (sCD163) simultaneously in patients with BD by considering their relationships with disease activity. Methods: The study group included 53 patients with BD (29 females and 24 males) and 30 healthy individuals. Patients with a lesion or active organ involvement were defined as active (n=39) and those without were identified as inactive (n=14). Serum sTWEAK and sCD163 concentrations were determined by enzyme-linked immunosorbent assay. Results: Serum sTWEAK and sCD163 levels were significantly increased in patients with BD compared with the healthy group (p=0.016 and p=0.003, respectively). Concentrations of these two molecules were also higher in active and inactive BD than the healthy individuals (p=0.043 for sTWEAK and p=0.010 for sCD163). Receiver operating characteristic curve analysis revealed that serum sCD163 and sTWEAK levels had a discriminating ability between patients with BD and healthy controls with area under the curve values of 0.706 and 0.661, respectively. Conclusion: It was concluded that circulating sTWEAK and its scavenger receptor sCD163 levels were increased in BD, significantly predicted the disease, and might be significant molecules to assess inflammation.

🔖

Bu Makaleye Atıf Yap

AKCAN, B., ARICA, D. A., YAMAN, S. O., BAHADIR, S., ÖREM, A., AKSAN, B., KURAL, B., YUCESAN, F. B. (2022). Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease. International Journal of Medical Biochemistry, Cilt: 5 - Sayı: 2, 89–95. https://ajindex.com/articles/541397

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Yazıcı Y, Yazıcı H, editors. Behcet’s Syndrome. New York: Springer; 2010
  2. Leccese P, Alpsoy E. Behçet's Disease: An Overview of Etiopathogenesis. Front Immunol 2019;10:1067
  3. Gül A. Pathogenesis of Behçet's disease: autoinflammatory features and beyond. Semin Immunopathol 2015;37(4):413–8
  4. Becatti M, Emmi G, Bettiol A, Silvestri E, Di Scala G, Taddei N, et al. Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects. Clin Exp Immunol 2019;195(3):322–33
  5. Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet's disease. Autoimmun Rev 2012;11(10):699–704
  6. Greco A, De Virgilio A, Ralli M, Ciofalo A, Mancini P, Attanasio G, et al. Behçet's disease: New insights into pathophysiology, clinical features and treatment options. Autoimmun Rev 2018;17(6):567–75
  7. Menyawi ME, Fawzy M, Al-Nahas Z, Edris A, Hussein H, Shaker O, et al. Serum tumor necrosis factor alpha (TNF-a) level in patients with Behçet’s disease: Relation to clinical manifestations and disease activity. Egypt Rheumatol 2014;36:139–43
  8. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza MH, Ayed K. Cytokine profile in Behçet's disease patients. Scand J Rheumatol 2002;31(4):205–10
  9. Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gonçalves O, et al. Behçet's disease--a contemporary review. J Autoimmun 2009;32(3–4):178–88
  10. Pay S, Şimşek I, Erdem H, Dinç A. Immunopathogenesis of Behçet’s disease with special emphasize to the possible role of antigen presenting cells. Rheumatol Int 2007;27:417–24
  11. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487–501
  12. Bodmer J, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002;27:19–26
  13. Nakhjavani MR, Abediazar S, Ghorbanihaghjo A, Esmaeili N, Pourlak T, Zununi Vahed S. Serum tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and IL-17 levels are associated with disease activity in systemic lupus erythematosus patients with and without nephritis. J Renal Inj Prev 2019;8(3):204–10
  14. Park MC, Chung SJ, Park YB, Lee SK. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol 2008;37(3):173–8
  15. Kaplan M, Yuksel M, Ates I, Yalın Kilic ZM, Kilic H, Ates H, et al. Are sTWEAK and IL-17A levels in ınflammatory bowel disease associated with disea